Research on the Safety and Efficacy of Intraoperative Radiation Therapy in Malignant Cerebral Tumor

Launched by FIRST AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY · Apr 15, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to treat malignant brain tumors, particularly glioblastoma, which is a type of aggressive brain cancer. The researchers want to see if a treatment called intraoperative radiation therapy, given during surgery, can make it safer and more effective for patients. This method aims to target the tumor more precisely and improve patients' chances of living longer and better after treatment.

To participate in this trial, patients need to be between 18 and 75 years old and have been diagnosed with a high-grade glioma or another serious brain tumor. They should be in reasonably good health, with no other major health issues that could affect their treatment or recovery. If you join the trial, you'll undergo surgery to remove the tumor, and during the surgery, you'll receive this special radiation treatment. The study is currently not recruiting participants, but it aims to help improve outcomes for people facing these challenging diagnoses.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18-75 years old, non-pregnant or lactating women
• • KPS ≥60
• • MRI and CT of the brain with contrast should be considered for diagnosis of high-grade glioma or other malignant brain tumors
• • No other underlying diseases that affect survival time, follow-up or quality of life, and no other serious organic lesions
• • Not receive radiotherapy, chemotherapy and other treatment methods for intracranial lesions in the past;
• • Tumor located supratentorium, and the position should ensure that the tumor resection volume is more than 90%;
• • The required dose of standard radiotherapy exceeds normal tissue tolerance
• • No related contraindications such as intraoperative radiotherapy and craniotomy.
• Exclusion Criteria:
• • Refuse to undergo craniotomy or radiation therapy;
• • The postoperative paraffin pathological results were not high-grade gliomas or other cranial malignant tumors;
• • Refuse to participate in the clinical trial after informed consent without the above exclusion criteria.